Covidien is investing $45 million over a three-year period in the more than 100,000 square-foot facility. It will eventually employ more than 300 people.
The facility has two core focuses, according to the company: 1) Identify and develop products that are customized to meet the needs of China and other emerging markets; and 2) Utilize the unique skillsets and expertise of employees in Asia to create and develop new medical device technologies.
“Establishing this research and development facility in Shanghai reinforces Covidien’s continued commitment to providing innovative new products that will help healthcare providers worldwide improve patient care and extend healthcare delivery to more people and more places,” said José E. Almeida, chairman, president and CEO of Covidien, in the release. “China is a key market in our global strategy, and this investment is a reflection of our strategic initiatives.”
This is not Covidien’s first facility in China. The company has other operations in the country, including 10 commercial offices, a manufacturing center and training facilities for healthcare professionals.
Covidien has its U.S. headquarters in Mansfield, Mass.
Related Articles on Medical Devices:
Solos Endoscopy Launches Bariatric Instruments
Cook Medical Scraps Plans for Five New Midwest Plants
Reflectance Medical Receives FDA Clearance for Oximeter
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
